Lyra Therapeutics Statistics Share Statistics Lyra Therapeutics has 1.64M
shares outstanding. The number of shares has increased by 1.24%
in one year.
Shares Outstanding 1.64M Shares Change (YoY) 1.24% Shares Change (QoQ) 0.59% Owned by Institutions (%) 37.95% Shares Floating 1.64M Failed to Deliver (FTD) Shares 683 FTD / Avg. Volume 1.53%
Short Selling Information The latest short interest is 45.6K, so 2.77% of the outstanding
shares have been sold short.
Short Interest 45.6K Short % of Shares Out 2.77% Short % of Float 3.31% Short Ratio (days to cover) 6.25
Valuation Ratios The PE ratio is -7.19 and the forward
PE ratio is -0.69.
Lyra Therapeutics's PEG ratio is
-0.53.
PE Ratio -7.19 Forward PE -0.69 PS Ratio 438.05 Forward PS 6.8 PB Ratio 57.96 P/FCF Ratio -9.29 PEG Ratio -0.53
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Lyra Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.41,
with a Debt / Equity ratio of 2.97.
Current Ratio 3.41 Quick Ratio 3.41 Debt / Equity 2.97 Debt / EBITDA -0.57 Debt / FCF -0.48 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $51.13K Profits Per Employee $-3.11M Employee Count 30 Asset Turnover 0.02 Inventory Turnover n/a
Taxes Income Tax 39K Effective Tax Rate -0.04%
Stock Price Statistics The stock price has increased by -51.74% in the
last 52 weeks. The beta is 0.17, so Lyra Therapeutics's
price volatility has been higher than the market average.
Beta 0.17 52-Week Price Change -51.74% 50-Day Moving Average 7.07 200-Day Moving Average 8.44 Relative Strength Index (RSI) 43.01 Average Volume (20 Days) 44,726
Income Statement In the last 12 months, Lyra Therapeutics had revenue of 1.53M
and earned -93.44M
in profits. Earnings per share was -1.43.
Revenue 1.53M Gross Profit 1.53M Operating Income -96.35M Net Income -93.44M EBITDA -60.26M EBIT -60.73M Earnings Per Share (EPS) -1.43
Full Income Statement Balance Sheet The company has 40.58M in cash and 34.38M in
debt, giving a net cash position of 6.2M.
Cash & Cash Equivalents 40.58M Total Debt 34.38M Net Cash 6.2M Retained Earnings -404.79M Total Assets 52.57M Working Capital 19.9M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -70.01M
and capital expenditures -2.34M, giving a free cash flow of -72.35M.
Operating Cash Flow -70.01M Capital Expenditures -2.34M Free Cash Flow -72.35M FCF Per Share -1.11
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -6280.83% and -6090.94%.
Gross Margin 100% Operating Margin -6280.83% Pretax Margin -6088.4% Profit Margin -6090.94% EBITDA Margin -3928.42% EBIT Margin -6280.83% FCF Margin -4716.36%
Dividends & Yields LYRA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for LYRA is $16,
which is 146.2% higher than the current price. The consensus rating is "Hold".
Price Target $16 Price Target Difference 146.2% Analyst Consensus Hold Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 28, 2025. It was a
backward
split with a ratio of 1:50.
Last Split Date May 28, 2025 Split Type backward Split Ratio 1:50
Scores Altman Z-Score -12.81 Piotroski F-Score 2
